ML 23 | 115007-18-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ML 23
• 英文别名: N-2,4-dinitrophenyl-5-methoxy-tryptamine；N-(2,4-Dinitrophenyl)-5-methoxytryptamine；N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-2,4-dinitroaniline
• CAS: 115007-18-6
• 化学式: C₁₇H₁₆N₄O₅
• 分子量: 356.338
• InChiKey: ODQMCTXUHFTMIE-UHFFFAOYSA-N

物化性质

• 沸点：
  624.0±55.0 °C(Predicted)
• 密度：
  1.447±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-甲氧基色胺 、 sodium bicarbonate (NaHCO3) 、 2,4-二硝基氟苯 生成 ML 23
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them
  申请人：——

  公开号：US20040029950A1

  公开（公告）日：2004-02-12

  This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence.

  本发明涉及新型取代色胺和相关衍生物，以及从中制备的药物组合物。这些化合物、组合物及其盐可用于制造与褪黑激素系统相互作用的药物。这些化合物和条件可用于治疗多种类型的医疗状况，如中枢神经系统和精神障碍（睡眠障碍、癫痫和其他惊厥性障碍、焦虑、神经退行性疾病）、以生物钟为基础的障碍（时差反应、延迟睡眠综合症、倒班工作、季节性情感障碍）、肿瘤状况以及与衰老相关的状况。
• Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
  申请人：Zisapel Nava

  公开号：US20050020664A1

  公开（公告）日：2005-01-27

  This invention relates to the administration of novel substituted tryptamines and related derivatives for the treatment of several types of medical conditions, such as prostate conditions, impotence, cardiovascula disorders, central nervous system and psychiatric disorders (such as sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (such as jet lag, delayed sleep syndrome, shift-work-associated sleep disorder or seasonal affective disorder), endocrine indications, neoplastic conditions, conditions associated with senescence, ophthalmological diseases, cluster headaches and migraines, and weight gain disorders.

  本发明涉及使用新型取代色胺和相关衍生物治疗多种医疗状况，例如前列腺疾病、阳痿、心血管疾病、中枢神经系统和精神疾病（如睡眠障碍、癫痫和其他惊厥性疾病、焦虑、神经退行性疾病）、基于生物钟的疾病（如时差反应、延迟睡眠综合症、轮班工作相关的睡眠障碍或季节性情感障碍）、内分泌症状、肿瘤疾病、与衰老有关的疾病、眼科疾病、集群头痛和偏头痛以及体重增加疾病。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation with sabcomelin
  申请人：Braincells, Inc.

  公开号：EP2258359A2

  公开（公告）日：2010-12-08

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation
  申请人：Braincells, Inc.

  公开号：EP2275095A2

  公开（公告）日：2011-01-19

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。